Meanwhile, higher expression of KIR2DL3, a receptor that inhibits NK cell activation, has been reported in stage III and IV melanoma patients compared to stage I melanoma, and several clinical trials are underway to test inhibitors, including Lirilumab and ASP98374 [29]. The gene discussed is KIR2DL3; the disease is melanoma.